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Abstract
We studied 17,576 members of 166 MLH1 and 224 MSH2 mutation-carrying families from the
Colon Cancer Family Registry. Average cumulative risks of colorectal cancer (CRC), endometrial
cancer (EC) and other cancers for carriers were estimated using modified segregation analysis
conditioned on ascertainment criteria. Heterogeneity in risks was investigated using a polygenic
risk modifier. Average CRC cumulative risks to age 70 years (95% confidence intervals) for
MLH1 and MSH2 mutation carriers, respectively, were estimated to be 34% (25%-50%) and 47%
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(36%-60%) for male carriers and 36% (25%-51%) and 37% (27%-50%) for female carriers.
Corresponding EC risks were 18% (9.1%-34%) and 30% (18%-45%). A high level of CRC risk
heterogeneity was observed (p<0.001), with cumulative risks to age 70 years estimated to follow
U-shaped distributions. For example 17% of male MSH2 mutation carriers have estimated lifetime
risks of 0-10% while 18% have risks of 90-100%. Therefore, average risks are similar for the two
genes but there is so much individual variation about the average that large proportions of carriers
have either very low or very high lifetime cancer risks. Our estimates of CRC and EC cumulative
risks for MLH1 and MSH2 mutation carriers are the most precise currently available.
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Introduction
DNA mismatch repair (MMR) genes encode proteins which detect and repair DNA
mismatches that can occur during cell replication(Aaltonen, et al., 1994). A person with a
germline mutation in any of the MMR genes MSH2, MLH1, MSH6 or PMS2 (MIM 120436,
609309, 600678, 600259) has an increased risk of colorectal carcinoma (CRC), endometrial
carcinoma (EC) and cancers of the stomach, ovary, ureter, renal pelvis, brain, small bowel,
hepatobiliary tract (Umar, et al., 2004) and possibly the breast (Jensen, et al., 2010; Lynch,
et al., 1988; Walsh, et al., 2010; Win, et al., 2012), prostate (Grindedal, et al., 2009; Soravia,
et al., 2003) and pancreas (Kastrinos, et al., 2009). Carriers of deleterious MMR gene
mutations who develop cancers with MMR deficiency are said to have Lynch syndrome
(MIM 120435), formerly known as hereditary nonpolyposis colorectal cancer (HNPCC)
(Jass, 2006). Lynch syndrome is the most common genetic CRC syndrome (Southey, et al.,
2005; Wagner, et al., 2003; Wijnen, et al., 1997) and 70-85% of Lynch syndrome is caused
by mutations in MLH1 or MSH2 (Barnetson, et al., 2006; Hampel, et al., 2005; Southey, et
al., 2005).
While it is known that carriers of germline mutations in MLH1 and MSH2 have high lifetime
cumulative risks (penetrance) of CRC, EC and other cancers, estimates of these risks are
imprecise (see Supp. Tables S1 and S2). It is also not known whether the estimates derived
from carriers identified from familial cancer clinics are applicable to carriers sampled
without regard to family histories of cancer. If heritable modifiers of risk exist then carriers
with strong family histories of cancer would be expected to carry, on average, more familial
disease-causing factors and hence to have greater cancer risks. However, the amount of
variability in cancer risks between carriers has not been previously estimated.
Precise estimates of the average age-specific cumulative risks for MLH1 and MSH2
mutation carriers are needed for sound genetic counselling of carriers and their relatives, for
choosing optimal surveillance strategies for known carriers and for the efficient
identification of carriers based on their family histories of cancer using risk prediction
models. The extent of variability in these risks is also of biological, epidemiological and
clinical interest. We therefore estimated cancer risks for MLH1 and MSH2 mutation carriers
as well as the variability in these risks using one of the largest series of MMR gene
mutation-carrying families in the world.
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Subjects were from all families recruited between 1997 and 2010 by the Colon Cancer
Family Registry (Colon CFR; see (Newcomb, et al., 2007) for a detailed description) in
which a deleterious mutation in MLH1 and MSH2 has been identified. Mutations were
considered pathogenic if the sequence variant results in a stop codon, a large duplication or
deletion, a frameshift mutation or a missense mutation previously reported in the scientific
literature as being pathogenic. All participants who donated blood samples or completed
questionnaires gave written, informed, consent for their data and biospecimens to be used in
approved Colon CFR projects. The present study has been approved by the Colon CFR
Steering Committee (project number C-CP-0606-03) and by the institutional human ethics
committees of all participating centres.
Families were recruited via probands who were either recently diagnosed CRC cases
ascertained through population-complete cancer registries in the USA (Puget Sound,
Washington State; the State of Minnesota; Los Angeles, California; Arizona; Colorado; New
Hampshire; North Carolina; and Hawaii), Australia (Victoria) and Canada (Ontario)
(population-based recruitment) or were persons from multiple-case families referred to
family cancer clinics in Australia (Melbourne, Adelaide, Perth, Brisbane, Sydney), New
Zealand (Auckland) and the USA (Mayo Clinic, Rochester, Minnesota and Cleveland)
(clinic-based recruitment). Probands were asked for permission to contact their relatives to
seek their enrollment in the Colon CFR. For population-based families, first-degree relatives
of probands were recruited at all centers and recruitment was extended to more distant
relatives at some centres. For clinic-based families, there were pre-specified rules, consistent
across centres, governing which family members were to be approached for recruitment.
Written informed consent was obtained from all study participants and the study protocol
was approved at each Colon CFR site.
Standardized questionnaires were used to collect data on each participant and his or her first-
and second-degree relatives, including their sexes, cancer sites and dates of birth, death (if
applicable), onset of any cancer and any prophylactic surgery to the colon, rectum,
endometrium or cervix. Validation was sought for all reported diagnoses of CRC and, at
some centres, for all invasive cancers. In this paper, hepatobiliary cancer means cancer of
the liver, gall bladder and biliary tract while urinary tract cancer means cancer of the
bladder, ureter, renal pelvis and kidney. Due to a lack of access to pathology reports, we
could not differentiate cancers of the renal pelvis from other kidney cancers nor
adenocarcinomas of the cervix from squamous cell carcinomas.
For population-based families, subjects were restricted to probands and their first- and
second-degree relatives. For clinic-based families, all available family members were
included in the analysis. Five probands with de novo mutations(Win, et al., 2011c) (two in
MLH1 and three in MSH2) and their families could not be easily included in the segregation
analyses so were excluded from all analyses. Families who were recruited through separate
probands but found to contain members in common were combined, giving nine families
which each had two probands, and these families were treated as clinic-based in the
segregation analyses. All ages were truncated at age 80 years and subjects for whom sex was
unknown were censored at birth. Affected subjects with missing ages at diagnosis
(comprising 14% of CRC diagnoses, 8% of EC diagnoses and 22% of non-colorectal, non-
endometrial (NCNE) Lynch cancer diagnoses) were included in the analysis by
marginalizing over the missing ages (see Statistical methods). Unaffected subjects with
missing ages were censored at birth, effectively removing them from the analysis, since their
affected statuses were considered to be unreliable.
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Standardized protocols were used to obtain and prepare biospecimens and to conduct all
laboratory analyses. Sequence variants in MLH1 and MSH2 were termed ‘mutations’ if they
encoded stop codons, large duplications or deletions, frameshift mutations or one of the
missense mutations previously reported in the scientific literature as being pathogenic.
Screening for germline mutations in MLH1 and MSH2 (and, at some centres, in MSH6 and
PMS2) was performed for all clinic-based probands and for those population-based probands
whose colorectal tumours displayed impaired MMR function, as evidenced by either
microsatellite instability or the absence of MMR protein expression in
immunohistochemical assays. Mutation testing was performed by Sanger sequencing or
denaturing high pressure liquid chromatography (dHPLC), followed by confirmatory DNA
sequencing(Newcomb, et al., 2007; Southey, et al., 2005). Large duplications and deletions
in MMR genes were detected by multiplex ligation-dependent probe amplification (MLPA)
according to the manufacturer's instructions (MRC Holland, Amsterdam, The Netherlands).
Each participant who donated a blood sample and was related to a mutation-carrying
proband underwent genetic testing for the proband's mutation.
Statistical methods
Mean ages at diagnosis and the corresponding sample standard deviations were calculated
for various cancer sites using R version 2.11.1 (R Development Core Team(Team, 2010)).
Probands and cases with missing or imputed ages at diagnosis were excluded from this
descriptive analysis.
Age-specific hazard ratios (HRs), i.e. the age-specific cancer incidence for carriers divided
by that for the population, were estimated using modified segregation analysis (Antoniou, et
al., 2001; Lange, 2002) (as described in detail in Supplementary Statistical Methods). This
analytical method is not subject to population stratification, can be rigorously adjusted for
many methods of ascertainment and uses data on all study participants, whether genotyped
or not, thereby maximising statistical power. Models were fitted by the method of maximum
likelihood using MENDEL (Lange, et al., 1988) version 3.2 and were appropriately adjusted
for the clinic- and population-based ascertainment of study participants using a combination
of retrospective likelihood and ascertainment-corrected joint likelihood (Antoniou, et al.,
2001; Gong, et al., 2010; Kraft and Thomas, 2000). More specifically, a conditional
likelihood was maximized where each pedigree's data was conditioned on the proband's
genotype, cancer status and age of onset (for population-based families) or on the proband's
genotype and the affected statuses and ages of onset of all family members at the time the
proband was found to be a MMR gene mutation carrier (for clinic-based families). HRs and
measures of risk heterogeneity were estimated and the corresponding cumulative risks, risk
distributions and 10-year risks were then derived from these estimates (see below).
Individuals were censored at the earliest of death, last known age alive, prophylactic surgery
(polypectomy, bowel surgery or hysterectomy) or the first diagnosis of cancer (as
applicable) so the resulting estimates describe risks of first primary cancers for people who
have not undergone prophylactic surgery, regardless of whether or not they are undergoing
surveillance. Censoring for surgery was site-specific, e.g. individuals were still considered to
be at risk of CRC following hysterectomy.
Two different genetic models were used in the modified segregation analyses: a major gene
model, in which only genotypes at the relevant MMR gene for each family were modelled,
and a mixed model, which incorporated an unmeasured polygene in addition to the major
gene (Antoniou, et al., 2001; Cannings, et al., 1978). All estimates presented in this paper
for cumulative risks, 10-year risks, estimates of risk heterogeneity and HRs for CRC and EC
were based on the mixed model. HR estimates for separate NCNE Lynch cancers and non-
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Lynch syndrome associated cancers were based on the major gene model, as were
hypothesis tests for the dependence of cancer risks on sex, gene, country, setting (clinic
versus population), mutation category, proband's age at onset and modelling assumptions.
The use of different genetic models for different purposes was necessary because simulation
has shown that major gene models are likely to give biased estimates of risk (Gong, et al.,
2010) but analyses using the mixed model were prohibitively slow to run so could not be
used to individually estimate a large number of parameters or to test a large number of
hypotheses. Therefore, a major gene model was used for model-building while the final
estimates of risk were based on a mixed model.
HRs for CRC, EC and NCNE Lynch cancers were estimated simultaneously to allow proper
adjustment for CRC-based ascertainment schemes when estimating the risks of non-CRC
cancers and to increase power (by helping the model identify likely carriers from the
placement of Lynch syndrome-associated cancers within each family). For each site, the age
at cancer diagnosis was modelled as a random variable whose hazard was the relevant
population incidence multiplied by a site-specific HR. Except when testing for differences in
risk by country, HRs were assumed to be independent of country of residence, as would be
expected if different population incidences only occur because of variation in the prevalence
of risk factors between countries and if these risk factors and MMR gene mutations all act
multiplicatively on the HR. The ages at diagnosis of different family members were
assumed to be conditionally independent given genotype, however residual correlation of
cancer within families was incorporated in most analyses by including an unmeasured
polygene (in addition to the major gene) in the definition of genotype (see below). As in
(Quehenberger, et al., 2005), the ages at diagnosis for different cancer sites within the same
individual were assumed to be conditionally independent, given genotype, until diagnosis of
the first cancer. Missing ages at diagnosis were treated using the standard method for
missing data in likelihood-based estimation, namely marginalization (integration) over all
missing values before maximizing the likelihood function (Little and Rubin, 2002).
Results
Our analyses were based on 17,576 people from 166 families segregating MLH1 mutations
and 224 families segregating MSH2 mutations. Forty-eight (29%) of the MLH1 and 64
(29%) of the MSH2 mutation carrying families were population-based. Of all families, 253
(65%) carried a protein-truncating mutation while 137 (35%) carried another type of
pathogenic mutation. There were 160 (41%) families from Australasia (Australia and New
Zealand combined), 104 (27%) from Canada and 126 (32%) from USA.
Mutation-specific testing of those relatives of the probands who had provided blood samples
identified an additional 768 carriers and 1128 non-carriers. The number and average ages at
diagnosis of the first primary cancers of all cases, other than those of probands and cases
with unknown ages at diagnosis, are listed in Table 1. There were almost twice as many
extra-intestinal Lynch cancers (i.e. Lynch cancers other than those of the colon, rectum or
stomach) in MSH2 mutation-carrying families than in MLH1 mutation-carrying families.
The estimated average HRs for various cancers are given in Table 2.
Gene and sex
The estimated age-dependent CRC HRs for MSH2 mutation carriers were similar to those
for MLH1, with any differences consistent with chance (p=0.5 for females and p=0.9 for
males). Similarly, no statistically significant difference in EC risks between MLH1 and
MSH2 mutation carriers was observed (p=0.3) though the point estimates for MSH2 were
higher (see Table 2). CRC HRs for male MLH1 mutation carriers were higher than those for
Dowty et al. Page 5













female carriers (p=0.01) but no such difference by sex was detected for MSH2 mutation
carriers (p=0.8).
Mutation type and proband's age at diagnosis
Female MLH1 mutation carriers with protein-truncating mutations were estimated to have
CRC incidences 0.40 (95% confidence interval (CI) 0.16-0.98; p= 0.03) times those for
female MLH1 mutation carriers with other types of mutations. No other differences in risk
between families according to the type of mutation were observed for the other five
combinations of sex, gene and site (CRC, EC), raising the possibility that this marginally-
significant result is spurious.
For female MLH1 mutation carriers, the estimated CRC incidence varied between families
according to the age of diagnosis of the family's proband (a proxy for heritable risk
modifiers), being lower by a factor of 0.94 (95% CI 0.90-0.98; p<0.001) for every year of
increase in the proband's age at diagnosis. No other differences in risk were observed for any
other combinations of sex, gene and site.
Setting and country
No differences were observed between clinic- and population-based families for either CRC
or EC risks except that female MLH1 mutation carriers were estimated to have incidences of
CRC which are 2.2 times (95% CI: 1.2-4.0; p=0.03) higher in the clinic-based setting.
No differences between countries were observed for CRC or EC risks except for the CRC
risks of female carriers. Female carriers from Canada and USA, respectively, were estimated
to have CRC incidences equal to those of carriers from Australasia multiplied by factors
(95% CI) of 0.44 (0.22-0.87) and 0.31 (0.14-0.71) for MLH1 (p=0.01) and 2.2 (0.81-5.8) and
0.85 (0.28-2.6) for MSH2 (p=0.02).
Cancer sites not currently included in the Lynch syndrome tumour spectrum
There was no evidence that male carriers had higher than population-levels of cancer risks at
any of the non-Lynch syndrome-associated cancer sites considered (listed in Table 2) except
that male MSH2 mutation carriers had incidences of pancreatic cancer estimated to be 18.1
times (95% CI: 8.4-39.0; p<0.001) the population rates. For female MLH1 and MSH2
mutation carriers, cervical cancer incidences were estimated to be 5.5 (95% CI: 1.7-17.7;
p=0.01) and 9.7 (95% CI: 3.8-24.8; p<0.001) times the population incidences, respectively.
No increased risks were observed for MLH1 and MSH2 mutation carriers at any other sites,
notably not for breast cancer (p=0.8 and 0.3, respectively) or prostate cancer (p=0.7 and 0.9,
respectively). The CIs for the HR estimates give likely upper bounds for the true breast and
prostate HRs (respectively) of 2.6 and 2.5 for MLH1, and 3.3 and 2.3 for MSH2.
Risk heterogeneity
There was strong evidence for large heterogeneity in the CRC and EC risks for carriers
about the average risks (p<0.001), with the standard deviation of the polygenic component
of risk estimated to be 1.6 (95% CI: 1.1-2.1) for CRC and 1.2 (95% CI: 0.1-2.2) for EC.
Figure 1 illustrates the predicted U-shaped distribution of lifetime risks of CRC. The
standard deviation of the polygenic component of CRC risk was also estimated separately
for population- and clinic-based families and found to be 1.5 (95% CI: 1.2-1.8) and 2.0
(95% CI: 1.4-2.7) respectively, consistent with no difference between the two settings
(p=0.1).
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Cumulative risks and 10-year risks
The estimated average age-specific cumulative risks of CRC, EC and other cancers for
carriers from USA are given in Table 3 and illustrated in Figure 2. It is estimated that 34%
(95% CI: 25-50) and 47% (95% CI: 36-60) of male MLH1 and MSH2 mutation carriers
(respectively) will be diagnosed with CRC by the age of 70 years. Of all female MLH1 and
MSH2 mutation carriers, an estimated 36% (95% CI: 25-51) and 37% (95% CI: 27-50)
respectively will be diagnosed with CRC by the age of 70 years while 18% (95% CI: 9.1-34)
and 30% (95% CI: 18-45) respectively will develop EC. Ten-year risks of cancer for
unaffected carriers from USA at various ages are given in Table 4. Corresponding results for
carriers from Australasia and Canada are given in Supp. Tables S3 - S6 and Figure 2.
Discussion
Our estimates of the average risks of CRC to age 70 years are broadly consistent with the
estimates of previous studies that have correctly adjusted for ascertainment (see Supp. Table
S1). In summary, we observed no differences between the CRC HRs for MLH1 and MSH2
mutation carriers, though malecarriers had higher CRC HRs than female carriers for MLH1
but not MSH2 (see Table 2). Evidence that CRC and EC risks depended on setting (clinic
versus population) was weak or absent, consistent with no difference by setting, perhaps
because family cancer clinics tend to genetically test families with histories of cancer which
are less severe now than they were in the past. The estimated 10-year risks of CRC for
unaffected carriers at various ages were roughly constant from the fifth decade of life
onwards (see Table 4), suggesting that aggressive surveillance is as important for older
mutation carriers as it is for younger ones.
Despite our study participants being drawn from countries with low population incidences of
stomach cancer, we found relatively high risks of stomach cancer in MLH1 and, to a lesser
extent, MSH2 mutation carriers. Imprecision in these estimates warrants caution but they
highlight potential benefits of gastroscopy screening, as suggested by (Capelle, et al., 2010).
Differences in the estimated stomach cancer risks between male MLH1 and MSH2 mutation
carriers could be due to differences in the true risks, imprecision in the HR estimates,
younger ages at onset for MLH1 mutation carriers, a higher proportion of MLH1 mutation
carriers among the stomach cancer cases than MSH2 mutation carriers or a combination of
these.
We assessed risks at cancer sites not currently part of the Lynch syndrome tumour spectrum
and found strong evidence for higher incidences of pancreatic cancer, in agreement with a
previous study (Kastrinos, et al., 2009), but no evidence for higher incidences of breast or
prostate cancer (all p>0.3), though we can't rule out 2- or 3-fold increased risks, consistent
with (Win, et al., 2012) (though this study partly overlaps with the present one). Despite
these null results, a number of studies have shown that breast and prostate cancers in carrier
families often show signs of MMR deficiency(Grindedal, et al., 2009; Jensen, et al., 2010;
Lynch, et al., 1988; Soravia, et al., 2003; Walsh, et al., 2010), suggesting some increase in
risk and a possible role for molecular characteristics of these tumours in predicting carrier
status. We also found a higher risk for cervical cancer, though this could be due to
misclassification of adenocarcinomas of the lower uterine segment.
Using a polygenic model of risk heterogeneity, we found very strong evidence that CRC and
EC risks are highly heterogeneous, as has been observed anecdotally by a leading clinician
(Henry Lynch, personal communication). Our estimates of the size of this risk heterogeneity
imply that a substantial proportion of mutation carriers are at population-level risk while a
significant minority are almost certain to develop CRC. The U-shapes of the histograms of
Figure 1 are not likely to be caused by the mixture of countries, settings (clinic versus
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population) or mutation types (protein-truncating versus all other types) of our study
participants because direct tests for differences in CRC risks by these characteristics found
weak or no effects, whereas the estimated risk heterogeneity was quite large. Similarly, the
risk heterogeneity is not likely to be caused by differences in screening practices between
families since the effect of this must be weaker than that of polypectomy which roughly
halves the risk (Jarvinen, et al., 2000). The estimated standard deviation for the polygenic
component of CRC risk was 1.6, which corresponds to a relative risk of 3.6 associated with
having an affected first-degree relative with early-onset disease (Pharoah, et al., 2002). The
cause of this risk heterogeneity is unknown but its size is consistent with the existence of
approximately 100 modifier SNPs, each with an HR of 1.05 and a minor allele frequency of
50%, acting independently and multiplicatively to alter the CRC risks for carriers. However,
it could also be caused by environmental factors which are correlated within families or by
mutation-specific penetrances. To date, only a few genetic variants and environmental risk
factors have been found to modify the cancer risks of MMR gene mutation carriers (Botma,
et al., 2010; Campbell, et al., 2007; Diergaarde, et al., 2007; Felix, et al., 2006; Frazier, et
al., 2001; Kruger, et al., 2007; Pande, et al., 2008; Pande, et al., 2010; Reeves, et al., 2008;
Talseth-Palmer, et al., 2011; Wijnen, et al., 2009; Win, et al., 2011a; Win, et al., 2011b) and
these reports have not been replicated by large studies. Large genome-wide association
studies of mutation carriers, similar to those carried out for BRCA1 and BRCA2 by the
CIMBA consortium (Couch and Wang, 2009), are needed.
The largest study of cancer risks for MLH1 and MSH2 mutation carriers to date (Bonadona,
et al., 2011) provided estimates that either agree with our results or are consistent with them.
However, our estimates are far more precise, with CIs half as wide, probably due to the fact
that the families of Bonadona et al. were all clinic-based while our study also included
population-based families which are more informative in penetrance analyses because they
require a less stringent adjustment for ascertainment. We also note that the study of
Bonadona et al. did not allow for any risk heterogeneity so their estimates are probably
downwardly biased (Gong, et al., 2010). For the same reason, the cumulative risks of
(Quehenberger, et al., 2005) are also likely to be underestimates.
Our study has several notable strengths. It is one of the largest studies so far to estimate the
penetrance of MLH1 and MSH2 mutations and it included population-based families.
Standardized questionnaires and protocols were used by the six different study sites
comprising the Colon CFR, ensuring a high degree of homogeneity across sites. Systematic
attempts were made to verify all reports of CRC and (at some Colon CFR sites) all cancers,
using pathology reports, medical records, corroboration by relatives, cancer registry reports
and/or death certificates (where available). Lastly, sophisticated statistical techniques were
used which properly adjusted for ascertainment, accounted for residual familial aggregation
of disease (thereby avoiding bias) and made use of data on all family members, whether
genotyped or not (thereby maximizing statistical power). The main weaknesses of our study
are its incomplete validation of cancers and that we could not adequately differentiate
between cancers within the same organ. Another weakness, shared by all Lynch syndrome
penetrance studies, was the need to either assume non-informative censoring at polypectomy
(the approach of our study and most others) or to make speculative assumptions about CRC
risks after polypectomy.
We have obtained unbiased estimates of CRC and EC penetrance for MLH1 and MSH2
mutation carriers which are more precise than any currently available. These estimates will
be useful for genetic counselling, designing optimal surveillance strategies for carriers and
as the key ingredient for risk prediction models which identify likely carriers from their
cancer family histories. We have also shown that penetrance varies greatly between carriers,
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perhaps due to genetic or environmental risk factors, with some mutation carriers at
population levels of risk and others almost certain to develop CRC.
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The estimated distribution of colorectal cancer cumulative risk to age 70 years for each
combination of gene and sex. For example, from the leftmost black bar, 17% of male MSH2
mutation carriers are estimated to have a less than 10% chance of developing colorectal
cancer by age 70 years.
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Colorectal cancer cumulative risks for males (A) and females (B) and endometrial cancer
cumulative risks for females (C). Cumulative risks are for MLH1 mutation carriers
(unbroken lines), MSH2 mutation carriers (dashed lines) and the general population (dotted
lines) living in Australia and New Zealand (light grey), Canada (dark grey) and USA
(black).
Dowty et al. Page 13











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Hum Mutat. Author manuscript; available in PMC 2014 January 09.
